Package: monitOS
Title: Monitoring Overall Survival in Pivotal Trials in Indolent
        Cancers
URL: https://opensource.nibr.com/monitOS/,
        https://github.com/Novartis/monitOS
BugReports: https://github.com/Novartis/monitOS/issues
Version: 0.2.0
Authors@R: c(
    person("Thomas", "Fleming", email = "fleming@seattlebiostat.com", role ="ctb"),
    person("Lisa", "Hampson", email = "lisa.hampson@novartis.com", role ="aut"),
    person("Bharani", "Bharani-Dharan", email = "bharani.bharani-dharan@novartis.com", role ="ctb"),
    person("Frank", "Bretz", email = "frank.bretz@novartis.com", role = "ctb"),
    person("Arunava", "Chakravartty", email = "arunava.chakravartty@novartis.com", role = "ctb"),
    person("Thibaud", "Coroller", email = "thibaud.coroller@novartis.com", role = c("aut", "cre")),
    person("Evanthia", "Koukouli", email = "evanthia.koukouli@novartis.com", role = "aut"),
    person("Janet", "Wittes", email = "janet@wittesllc.com", role = "ctb"),
    person("Nigel", "Yateman", email = "nigel.yateman@novartis.com", role = "ctb"),
    person("Emmanuel", "Zuber", email = "emmanuel.zuber@novartis.com", role = "ctb"),
    person("Novartis", "Pharma AG", role = "cph")
          )
Description: These guidelines are meant to provide a pragmatic, yet
        rigorous, help to drug developers and decision makers, since
        they are shaped by three fundamental ingredients: the
        clinically determined margin of detriment on OS that is
        unacceptably high (delta null); the benefit on OS that is
        plausible given the mechanism of action of the novel
        intervention (delta alt); and the quantity of information (i.e.
        survival events) it is feasible to accrue given the clinical
        and drug development setting. The proposed guidelines
        facilitate transparent discussions between stakeholders
        focusing on the risks of erroneous decisions and what might be
        an acceptable trade-off between power and the false positive
        error rate.
License: MIT + file LICENSE
Maintainer: Thibaud Coroller <thibaud.coroller@novartis.com>
Encoding: UTF-8
Roxygen: list(markdown = TRUE)
RoxygenNote: 7.3.2
Imports: bslib, stats, glue, shiny,
Suggests: testthat (>= 3.0.0), knitr, rmarkdown, pkgdown, shinylive
VignetteBuilder: knitr
Language: en-US
Config/pak/sysreqs: cmake make libuv1-dev zlib1g-dev
Repository: https://novartis.r-universe.dev
Date/Publication: 2026-04-15 19:17:12 UTC
RemoteUrl: https://github.com/novartis/monitos
RemoteRef: HEAD
RemoteSha: 7095b3f3d1676c041afc0138de8ec05ddbb95a11
NeedsCompilation: no
Packaged: 2026-06-14 08:15:20 UTC; root
Author: Thomas Fleming [ctb],
  Lisa Hampson [aut],
  Bharani Bharani-Dharan [ctb],
  Frank Bretz [ctb],
  Arunava Chakravartty [ctb],
  Thibaud Coroller [aut, cre],
  Evanthia Koukouli [aut],
  Janet Wittes [ctb],
  Nigel Yateman [ctb],
  Emmanuel Zuber [ctb],
  Novartis Pharma AG [cph]